vs

Side-by-side financial comparison of MEDIFAST INC (MED) and Stellar Bancorp, Inc. (STEL). Click either name above to swap in a different company.

Stellar Bancorp, Inc. is the larger business by last-quarter revenue ($108.9M vs $75.1M, roughly 1.5× MEDIFAST INC). On growth, Stellar Bancorp, Inc. posted the faster year-over-year revenue change (0.8% vs -36.9%). Stellar Bancorp, Inc. produced more free cash flow last quarter ($92.6M vs $-6.6M). Over the past eight quarters, Stellar Bancorp, Inc.'s revenue compounded faster (0.2% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Stellar Bancorp, Inc. is a United States-based financial holding company that operates via its wholly-owned banking subsidiary. It provides a full suite of retail and commercial banking services, including deposit products, personal and commercial loans, mortgage services, and wealth management solutions, serving individual consumers, small businesses, and regional corporate clients.

MED vs STEL — Head-to-Head

Bigger by revenue
STEL
STEL
1.5× larger
STEL
$108.9M
$75.1M
MED
Growing faster (revenue YoY)
STEL
STEL
+37.7% gap
STEL
0.8%
-36.9%
MED
More free cash flow
STEL
STEL
$99.2M more FCF
STEL
$92.6M
$-6.6M
MED
Faster 2-yr revenue CAGR
STEL
STEL
Annualised
STEL
0.2%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MED
MED
STEL
STEL
Revenue
$75.1M
$108.9M
Net Profit
$26.1M
Gross Margin
69.4%
Operating Margin
-10.4%
29.0%
Net Margin
24.0%
Revenue YoY
-36.9%
0.8%
Net Profit YoY
3.7%
EPS (diluted)
$-1.64
$0.52

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
STEL
STEL
Q4 25
$75.1M
$108.9M
Q3 25
$89.4M
$105.6M
Q2 25
$105.6M
$104.1M
Q1 25
$115.7M
$104.8M
Q4 24
$119.0M
$108.0M
Q3 24
$140.2M
$107.8M
Q2 24
$168.6M
$106.8M
Q1 24
$174.7M
$108.4M
Net Profit
MED
MED
STEL
STEL
Q4 25
$26.1M
Q3 25
$-2.3M
$25.7M
Q2 25
$2.5M
$26.4M
Q1 25
$-772.0K
$24.7M
Q4 24
$25.2M
Q3 24
$1.1M
$33.9M
Q2 24
$-8.2M
$29.8M
Q1 24
$8.3M
$26.1M
Gross Margin
MED
MED
STEL
STEL
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
MED
MED
STEL
STEL
Q4 25
-10.4%
29.0%
Q3 25
-4.6%
30.5%
Q2 25
-1.0%
31.7%
Q1 25
-1.1%
29.6%
Q4 24
0.6%
29.4%
Q3 24
1.5%
39.6%
Q2 24
-4.7%
35.1%
Q1 24
4.5%
30.4%
Net Margin
MED
MED
STEL
STEL
Q4 25
24.0%
Q3 25
-2.5%
24.3%
Q2 25
2.3%
25.3%
Q1 25
-0.7%
23.6%
Q4 24
23.3%
Q3 24
0.8%
31.4%
Q2 24
-4.8%
27.9%
Q1 24
4.8%
24.1%
EPS (diluted)
MED
MED
STEL
STEL
Q4 25
$-1.64
$0.52
Q3 25
$-0.21
$0.50
Q2 25
$0.22
$0.51
Q1 25
$-0.07
$0.46
Q4 24
$0.08
$0.47
Q3 24
$0.10
$0.63
Q2 24
$-0.75
$0.56
Q1 24
$0.76
$0.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
STEL
STEL
Cash + ST InvestmentsLiquidity on hand
$167.3M
$419.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$198.9M
$1.7B
Total Assets
$248.0M
$10.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
STEL
STEL
Q4 25
$167.3M
$419.5M
Q3 25
$173.5M
$728.4M
Q2 25
$162.7M
$578.1M
Q1 25
$164.6M
$560.6M
Q4 24
$162.3M
$911.2M
Q3 24
$170.0M
$516.2M
Q2 24
$163.5M
$490.3M
Q1 24
$156.4M
$399.7M
Stockholders' Equity
MED
MED
STEL
STEL
Q4 25
$198.9M
$1.7B
Q3 25
$214.7M
$1.7B
Q2 25
$216.0M
$1.6B
Q1 25
$211.0M
$1.6B
Q4 24
$210.1M
$1.6B
Q3 24
$207.3M
$1.6B
Q2 24
$205.3M
$1.6B
Q1 24
$211.0M
$1.5B
Total Assets
MED
MED
STEL
STEL
Q4 25
$248.0M
$10.8B
Q3 25
$268.2M
$10.6B
Q2 25
$269.3M
$10.5B
Q1 25
$280.0M
$10.4B
Q4 24
$284.2M
$10.9B
Q3 24
$291.2M
$10.6B
Q2 24
$293.5M
$10.7B
Q1 24
$302.8M
$10.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
STEL
STEL
Operating Cash FlowLast quarter
$-5.3M
$97.0M
Free Cash FlowOCF − Capex
$-6.6M
$92.6M
FCF MarginFCF / Revenue
-8.8%
85.0%
Capex IntensityCapex / Revenue
1.8%
4.0%
Cash ConversionOCF / Net Profit
3.71×
TTM Free Cash FlowTrailing 4 quarters
$1.2M
$173.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
STEL
STEL
Q4 25
$-5.3M
$97.0M
Q3 25
$12.1M
$63.6M
Q2 25
$-3.4M
$25.8M
Q1 25
$3.4M
$-5.7M
Q4 24
$-4.9M
$132.6M
Q3 24
$9.1M
$59.5M
Q2 24
$13.1M
$38.1M
Q1 24
$7.3M
$31.1M
Free Cash Flow
MED
MED
STEL
STEL
Q4 25
$-6.6M
$92.6M
Q3 25
$10.8M
$62.5M
Q2 25
$-4.8M
$24.5M
Q1 25
$1.9M
$-6.4M
Q4 24
$-7.2M
$128.0M
Q3 24
$7.7M
$57.7M
Q2 24
$11.1M
$37.1M
Q1 24
$5.4M
$30.5M
FCF Margin
MED
MED
STEL
STEL
Q4 25
-8.8%
85.0%
Q3 25
12.0%
59.2%
Q2 25
-4.5%
23.6%
Q1 25
1.6%
-6.2%
Q4 24
-6.1%
118.5%
Q3 24
5.5%
53.5%
Q2 24
6.6%
34.8%
Q1 24
3.1%
28.2%
Capex Intensity
MED
MED
STEL
STEL
Q4 25
1.8%
4.0%
Q3 25
1.5%
1.1%
Q2 25
1.3%
1.2%
Q1 25
1.3%
0.7%
Q4 24
1.9%
4.3%
Q3 24
1.0%
1.7%
Q2 24
1.1%
0.9%
Q1 24
1.1%
0.5%
Cash Conversion
MED
MED
STEL
STEL
Q4 25
3.71×
Q3 25
2.48×
Q2 25
-1.36×
0.98×
Q1 25
-0.23×
Q4 24
5.26×
Q3 24
8.04×
1.76×
Q2 24
1.28×
Q1 24
0.88×
1.19×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons